Caillat-Zucman S
Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Diderot, Paris, France.
HLA. 2017 Jan;89(1):3-13. doi: 10.1111/tan.12947.
Recent advances in technologies such as high density array-based genotyping, DNA and RNA deep sequencing, expression quantitative-trait loci mapping, epigenome analyses, and new computational strategies, have introduced drastic shifts into our understanding of major histocompatibility complex (MHC) association with immune-mediated diseases. Here, we review the most exciting findings in this field. We show how the fine characterization of structural features and expression levels of MHC alleles, posttranslational or environmental modifications of HLA-bound peptides, and epistatic interactions with non-HLA genes, has made it possible not only to provide mechanistic explanations for MHC associations with immune-mediated diseases but also to help choose relevant therapeutic targets.
诸如基于高密度阵列的基因分型、DNA和RNA深度测序、表达定量性状位点定位、表观基因组分析以及新的计算策略等技术的最新进展，已使我们对主要组织相容性复合体（MHC）与免疫介导疾病的关联的理解发生了巨大转变。在此，我们回顾该领域最令人兴奋的发现。我们展示了MHC等位基因的结构特征和表达水平的精细表征、HLA结合肽的翻译后修饰或环境修饰以及与非HLA基因的上位相互作用，如何不仅能够为MHC与免疫介导疾病的关联提供机制解释，还能有助于选择相关的治疗靶点。
